June 2 (Reuters) - VistaGen Therapeutics Inc VTGN.O:
VISTAGEN ON TRACK TO DELIVER TOPLINE DATA FROM FASEDIENOL PALISADE-3 PHASE 3 TRIAL FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER IN THE FOURTH QUARTER OF THIS YEAR
VISTAGEN THERAPEUTICS INC - PALISADE-4 PHASE 3 TRIAL RESULTS EXPECTED IN FIRST HALF OF 2026
Source text: ID:nBwNn1f5a
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))